News - Updated Product Information for Efexor

	Unregistered User Click here if this is not your Personal Edition
		Contact Us \| Free E-Mail Updates \| Journals \| Register a colleague

Depression

EXPLORE :

Most Read News

All News

All Webcasts / CME

All Cases

Congress Resource Centre

All Medical Resources

My Personal Edition

Warning | Privacy

Recent news - Depression

	Telephone-Delivered Collaborative Care for Treating Post-CABG Depression: A Randomized Controlled Trial - (JAMA)
	TopAbstracts in Depression 11/18/2009 - (DGNews)
	TopAbstracts in Depression 11/11/2009 - (DGNews)
	Evaluating the causal relevance of diverse risk markers: horizontal systematic review - (BMJ)
	Escitalopram Decreases Symptoms of Major Depressive Disorder in Adolescents: Presented at AACAP - (DGDispatch)

News archive

Recent webcasts/CME - Depression

Applying Evidence to Practice in Major Depressive Disorder: An Interactive Panel Discussion

Practical Considerations for Front-Line Therapy in MDD

Improving Outcomes and Overcoming Barriers in Treatment-Refractory MDD: Practical Strategies and Insights

	PreAnesthetic Assessment Undergoing Electroconvulsive Therapy
	Antidepressant-Induced Suicidality: Implications for Clinical Practice

Webcasts/CME archive

Recent cases - Depression

	Creutzfeldt-Jacob Disease Presenting as Severe Depression: A Case Report
	Sexual Dysfunction in a Young Mother
	Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
	A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
	Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report

Cases archive

my personal edition > depression > news

E-Mail this DGNews to a colleague

DGNews

Updated Product Information for Efexor

LONDON, U.K. -- May 31, 2006 -- The Medicines and Healthcare products Regulatory Agency (MHRA) has concluded its review into all the latest safety evidence relating to Efexor (venlafaxine), an antidepressant belonging to a class of medicines known as selective serotonin reuptake inhibitors (SSRIs).

The review particularly looked at the risks associated with overdose.

Updated prescribing advice is designed to minimise the risks of side effects, especially in overdose. The main points are:

The need for specialist supervision in those severely depressed or hospitalised patients who need doses of 300mg daily or more.
· Cardiac contra-indications are more targeted towards high risk groups.
· As previously, patients with uncontrolled hypertension should not take venlafaxine, and blood pressure monitoring is recommended for all patients.
· Updated advice on possible drug interactions.

In addition, a smaller pack size will soon be available to help minimise the risk of overdose.

The MHRA is informing healthcare professionals about the updated prescribing advice. The Patient Information Leaflet (PIL) will also be updated, incorporating all the new advice.

Dr June Raine, MHRA Director said, "We are writing to healthcare professionals to ensure that they are fully informed of the updated information on Efexor to allow them to make informed prescribing decisions. It is very important that patients do not stop their treatment. Patients already taking Efexor should make a routine appointment with their doctor, so that their treatment can be reviewed. For most patients, no changes to their treatment will be needed."

Patients and healthcare professionals are urged to report any suspected adverse reactions to Efexor via the Yellow Card Scheme. They can be completed on the web at www.yellowcard.gov.uk

SOURCE: Medicines and Healthcare Products Regulatory Agency

E-Mail this DGNews to a colleague To print, use this version